- Company
- Who will distribute Lamisil?
- by Jung, Hye-Jin Feb 13, 2020 06:28am
- GlaxoSmithKline Consumer Health's 'Lamisil' distribution network is distant. All rights reserved by Dong-wha have been transferred to Ildong. Only Lamisil has been missing and haven't found a supplier for over a month. Wholesalers and medical institutions are holding back their existing inventory and are very nervous about their short expi
- Policy
- COVID-19 primary antivirals Kaletra·Chloroquine recommended
- by Lee, Jeong-Hwan Feb 13, 2020 06:28am
- The central clinical TF will recommend antiretroviral agents Kaletra, antimalarial agents Chloroquine, and Hydroxychloroquine as the primary antiviral drugs for COVID-19. Ribavirin and Interferon, which are mentioned as COVID-19 drugs, have relatively high side effects and are not recommended as primary antiviral drugs. In particular, some
- Policy
- Antidepressant Pristiq’s first generic seeks approval
- by Lee, Tak-Sun Feb 13, 2020 06:27am
- Apparently, generic makers are knocking on the door of depression medication Pristiq ER tablet. This is the first time the original’s saline base-modified drug is applying for an approval. On Feb. 10, Korea’s Ministry of Food and Drug Safety (MFDS) notified the Pristriq’s patent holder Pfizer that a drug with desvenlafaxine, the origi
- Opinion
- [FOUCS] Fundamental issues with listed drug reevaluation
- by Kim, Jung-Ju Feb 13, 2020 06:27am
- The government is currently fine-tuning the detailed draft of Pharmaceutical Reevaluation Standard and Method. Although the initial drafting schedule disclosed at last year’s meeting with pharmaceutical industry and public hearing has been delayed, the government’s commitment on the task is still strong regardless of the urgent issues
- Policy
- Optimal substance derived by AI, entering clinical trials
- by Lee, Tak-Sun Feb 12, 2020 06:31am
- New drug candidates using the artificial intelligence (AI) drug development platform entered clinical trials for the first time in Korea. The company plans to develop the material as a new global drug. The Ministry of Food and Drug Safety approved the Phase I trial of PHI-101, a candidate for the treatment of acute myeloid leukemia (AML) f
- Company
- Yuhan and Eisai ink co-marketing deal for PPI Pariet
- by Eo, Yun-Ho Feb 12, 2020 06:31am
- Yuhan is to join the effort to market PPI medication Pariet in Korea. According to pharmaceutical industry sources, Pariet supplier Eisai Korea and Yuhan have signed a co-marketing contract on marketing and sales in Korea for proton pump inhibitor (PPI) medication Pariet (rabeprazole sodium) 5 mg as it has been listed for reimbursement s
- Policy
- “Outbreak spreading locally, need to deny Chinese traveler"
- by Lee, Jeong-Hwan Feb 12, 2020 06:31am
- Professor Choi Jae Wook at Korea University Department of Preventive Medicine raised his voice and said, “How could government affirm that the novel coronavirus has not started transmitting throughout Korea? This is the government mocking the people and medical experts. We should not ignore the possibility of the current number of confirmed
- Company
- Baxter-Boryung shake hands on comarketing PN in Korea
- by Eo, Yun-Ho Feb 12, 2020 06:28am
- Boryung Pharmaceutical is to reinforce the sales capacity in Korea for Baxter’s nutrition solution pipeline. Baxter (GM Hyun Dong-wook) announced on Feb. 10 of signing a business partnership agreement with Boryung Pharmaceutical (Co-CEO Ahn Jae-hyun, Lee Sam-soo) on co-marketing the company’s Olimer and two other major nutrition soluti
- Company
- Lipitor won the market in the 2010s
- by An, Kyung-Jin Feb 12, 2020 06:27am
- In the past decade, Lipitor, the hyperlipidemia drug, recorded the most outpatient prescriptions. Lipitor has been prescribed a total of &8361;1.31 trillion since 2010. After the patent expiration in 2009, even in the offensive of generic drugs, Lipitor showed that it never fell below the second place in prescriptions. The hepatitis B d
- Opinion
- [Reporter’s view]2019n-CoV & safety ignorance of companies
- by Kim, Jin-Gu Feb 12, 2020 06:27am
- Rumor has it that the new coronavirus confirmers 17 and 19 are employees of pharmaceutical companies. The fact is not known. However, it is speculated that they were attending a plastic surgery conference held in Singapore recently, and the KCDC confirmed that they are not doctors. More important than rumor is the possibility that pharm
